Phase 2 N=40 Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Macular Edema · Retinal Vein Occlusion
Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=30 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections
Phase 2 N=12 REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Macular Edema · Branch Retinal Vein Occlusion
Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart
N/A N=30 Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion
Central Retinal Vein Occlusion With Macular Edema
Primary: Visual Acuity — 0.32; 0.44 logMAR units
Phase 4 N=20 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters
Phase 3 N=283 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Macular Edema Secondary to Branch Retinal Vein Occlusion
Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6 — 12.5; 5.0 Letters — p=<0.001
Phase 4 N=202 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
Macular Edema
Primary: Trend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15 — 17.5; 19.7; 18.7; 21.0 Letters — p=0.5091
Phase 3 N=183 Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
Branch Retinal Vein Occlusion
Primary: Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF — 24; 48 participants — p=0.0003
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 2 N=9 Minocycline to Treat Branch Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months Compared to Baseline. — 5.3; 13.0 ETDRS letters
Phase 3 N=189 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Macular Edema Secondary to Central Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score — 64; 9 percentage of participants — p=< 0.0001
N/A N=45 Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Changes of Central Retinal Thickness — 510.35; 468.22; 291.48; 233.33 micrometer — p=0.60
N/A N=323 A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
Retinal Vein Occlusion · Macular Edema
Primary: Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence…
Phase 3 N=397 A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
Macular Edema · Retinal Vein Occlusion
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months — 54.7; 56.0; 53.0; 7.3 Units on a scale — p=<0.0001
Phase 2 N=16 Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
Central Retinal Vein Occlusion
Primary: Incidence and Severity of Ocular and Systemic Adverse Events — 1; 0; 0; 1 participants
Phase 3 N=682 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
Macular Edema, Cystoid · Retinal Vein Occlusion
Primary: The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit — 5…
Phase 3 N=66 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: Incidence of Serious Adverse Events. — 17 number of serious adverse events
Phase 3 N=357 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Macular Edema · Central Retinal Vein Occlusion
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters
Phase 3 N=177 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants…
Phase 3 N=455 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO) — 59.5; 56.6…
Phase 4 N=162 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
Central Retinal Vein Occlusion
Primary: The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to…
N/A N=30 A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
Central Retinal Vein Occlusion
Primary: Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts — 12.5; 14; 13.5 letters read correctly
Phase 4 N=71 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 6 — 51.90; 18.60 letters
Phase 3 N=40 Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
Retinal Vein Occlusion
Primary: Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex — 7; 5; 7; 4 participants
Phase 4 N=307 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
Retinal Vein Occlusion · Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) — 56.6; 59.2; 7.9; 16.9 letters
Phase 3 N=252 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Central Retinal Vein Occlusion
Primary: Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3 — 11.3; -2.7 Letters — p=<0.001
Phase 2 N=6 Minocycline to Treat Central Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: The Primary Outcome is the Comparison Between the Minocycline and Placebo Groups of the Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months…
Phase 3 N=568 A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
Macular Edema · Retinal Vein Occlusion
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in BRVO Participants. — 14.2; 15.6 ETDRS Letters — p=.0004
Phase 2 N=81 Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions
Retinal Vein Occlusion
Primary: Incidence and Severity of Ocular and Non-ocular Adverse Events. — 17; 12; 37; 35 participants
N/A N=375 Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 47.56; 5.09 Letters